Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOVIE INC.BIVI · Entity 7702 | Director | November 20, 2024 | January 07, 2025 |
| Celularity IncCELU · Entity 7145 | Director · Chief Executive Officer | April 13, 2026 | April 15, 2026 |
| Cryoport, Inc.CYRX · Entity 5125 | Director | June 05, 2026 | June 09, 2026 |
| MedAvail Holdings, Inc.MYOS · Entity 94590 | Director | March 31, 2020 | April 06, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOVIE INC.
Report date November 20, 2024 · Filed January 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.36 · Expires 2029-11-20 | Direct | 49,800 |
Reported balance
After 2024-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-11-20 · Grant · Acquired 49,800 · Balance 49,800 F1: The options vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2029-12-20 | Direct | 21,815 |
Reported balance
After 2024-12-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-20 · Grant · Acquired 21,815 · Balance 21,815 F2: The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting.
F2: The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026.
Celularity Inc
Report date April 13, 2026 · Filed April 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 2,853,553 |
Ending reported balance
After 2026-04-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-13 · Exercise / conversion · Acquired 3,281 · Balance 2,854,735 F1: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022. Row 2 · 2026-04-13 · Tax withholding · Disposed 1,182 · Balance 2,853,553 F2: This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-13 · Exercise / conversion · Disposed 3,281 · Balance 0 F3: Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock. F4: On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. The Class A Common Stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022.
F2: This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2026.
F3: Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock.
F4: On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. The Class A Common Stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4.
Cryoport, Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,625 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,350 · Balance 61,625 F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. |
| Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $15.70 · Expires 2033-06-05 | Direct | 16,077 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 16,077 · Balance 16,077 F2: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis.
F2: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026.
MedAvail Holdings, Inc.
Report date March 31, 2020 · Filed April 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 119,364 |
Reported balance
After 2020-03-31 transaction · row 1
1 source rowRow 1 · 2020-03-31 · Grant · Acquired 3,306 · Balance 119,364 F1: The shares of common stock were awarded to the reporting person under the registrant's 2012 Equity Incentive Plan and will vest immediately. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock were awarded to the reporting person under the registrant's 2012 Equity Incentive Plan and will vest immediately.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 01:07 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 16,077 | $0.00 Strike: $15.70 | $0.00 |
DisclosureSEC source: 0001104659-26-071507 · tm2617191-2_4seq1.xml · derivative · entry 2 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,077 Underlying: Common Stock · 16,077 shares Expires 2033-06-05 F2 · derivative.exercise_date: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 01:07 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 10,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071507 · tm2617191-2_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,625 F1 · security: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| April 13, 2026 Filed Apr 15, 2026 20:30 UTC | Celularity Inc CELU · Entity 7145 | Exercise / conversionRestricted Stock Units · Derivative | 3,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-016832 · ownership.xml · derivative · entry 3 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 3,281 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock. F4 · derivative.exercise_date: On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. The Class A Common Stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. The Class A Common Stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4. Read SEC document |
| April 13, 2026 Filed Apr 15, 2026 20:30 UTC | Celularity Inc CELU · Entity 7145 | Tax withholdingClass A Common Stock | 1,182 | $1.28 | $1,512.96 |
DisclosureSEC source: 0001493152-26-016832 · ownership.xml · nonDerivative · entry 2 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,853,553 F2 · kind: This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2026. Read SEC document |
| April 13, 2026 Filed Apr 15, 2026 20:30 UTC | Celularity Inc CELU · Entity 7145 | Exercise / conversionClass A Common Stock | 3,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-016832 · ownership.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,854,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022. F1 · shares: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 21:30 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001104659-25-089633 · tm2526007-1_4seq1.xml · derivative · entry 3 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The proceeds of the sale of Common Stock were used to pay the exercise price and withholding taxes due upon exercise of the Stock Option reported in this Form 4. F3 · derivative.exercise_date: 1/48 of the options vested on the 25th of each month for forty-eight months beginning on 9/25/2015. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 21:30 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 25,000 | $9.71 | $242,737.50 |
DisclosureSEC source: 0001104659-25-089633 · tm2526007-1_4seq1.xml · nonDerivative · entry 2 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,275 F1 · shares: The proceeds of the sale of Common Stock were used to pay the exercise price and withholding taxes due upon exercise of the Stock Option reported in this Form 4. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.50 to $9.8609, inclusive. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 21:30 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 50,000 | $2.66 | $133,000.00 |
DisclosureSEC source: 0001104659-25-089633 · tm2526007-1_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2025 Filed Aug 29, 2025 22:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 5,000 | $8.60 | $43,000.00 |
DisclosureSEC source: 0001104659-25-085826 · tm2524813-1_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,275 Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:24 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 41,098 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001104659-25-058267 · tm2517578-2_4seq1.xml · derivative · entry 2 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,098 Underlying: Common Stock · 41,098 shares Expires 2032-06-06 F2 · derivative.exercise_date: 1/12th of the options vest on the 6th of the month for twelve months beginning July 6, 2025. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:24 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 23,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-058267 · tm2517578-2_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,275 F1 · security: Reflects grant of restricted stock rights that vest in full on June 6, 2026, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on June 6, 2026, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| May 28, 2025 Filed May 30, 2025 23:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 12,500 | $6.10 | $76,250.00 |
DisclosureSEC source: 0001104659-25-055047 · tm2516629-1_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,061 Read SEC document |
| April 13, 2025 Filed Apr 15, 2025 20:30 UTC | Celularity Inc CELU · Entity 7145 | Exercise / conversionRestricted Stock Units · Derivative | 3,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-004823 · ownership.xml · derivative · entry 3 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,281 Underlying: Class A Common Stock · 3,281 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock. F4 · derivative.exercise_date: On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2025. The Class A Common Stock into which such vested RSUs converted on April 13, 2025 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2025. The Class A Common Stock into which such vested RSUs converted on April 13, 2025 is reported in Table I on this Form 4. Read SEC document |
| April 13, 2025 Filed Apr 15, 2025 20:30 UTC | Celularity Inc CELU · Entity 7145 | Tax withholdingClass A Common Stock | 1,154 | $1.64 | $1,892.56 |
DisclosureSEC source: 0001641172-25-004823 · ownership.xml · nonDerivative · entry 2 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,328 F2 · kind: This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2025. Read SEC document |
| April 13, 2025 Filed Apr 15, 2025 20:30 UTC | Celularity Inc CELU · Entity 7145 | Exercise / conversionClass A Common Stock | 3,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-004823 · ownership.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022. F1 · shares: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022. Read SEC document |
| April 13, 2025 Filed Jun 4, 2025 20:30 UTC Amendment | Celularity Inc CELU · Entity 7145 | Exercise / conversionRestricted Stock Units · Derivative | 3,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-013629 · ownership.xml · derivative · entry 3 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,281 Underlying: Class A Common Stock · 3,281 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock. F4 · derivative.exercise_date: On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2025. The Class A Common Stock into which such vested RSUs converted on April 13, 2025 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2025. The Class A Common Stock into which such vested RSUs converted on April 13, 2025 is reported in Table I on this Form 4. Read SEC document |
| April 13, 2025 Filed Jun 4, 2025 20:30 UTC Amendment | Celularity Inc CELU · Entity 7145 | Tax withholdingClass A Common Stock | 1,154 | $1.64 | $1,892.56 |
DisclosureSEC source: 0001641172-25-013629 · ownership.xml · nonDerivative · entry 2 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,851,454 F2 · kind: This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2025. Read SEC document |
| April 13, 2025 Filed Jun 4, 2025 20:30 UTC Amendment | Celularity Inc CELU · Entity 7145 | Exercise / conversionClass A Common Stock | 3,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-013629 · ownership.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,852,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022. F1 · shares: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A Common Stock. On April 13, 2022, the reporting person was granted 13,123 RSUs, 25% of which vested on April 13, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022. Read SEC document |
| December 20, 2024 Filed Jan 7, 2025 22:06 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 21,815 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001520138-25-000016 · ownership.xml · derivative · entry 2 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,815 Underlying: Common Stock · 21,815 shares Expires 2029-12-20 F2 · derivative.exercise_date: The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. Read SEC document |
| November 21, 2024 Filed Dec 3, 2024 00:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 2,500 | $6.48 | $16,200.00 |
DisclosureSEC source: 0001104659-24-124748 · tm2429945-1_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,561 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.40 to $6.60, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2024 Filed Jan 7, 2025 22:06 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 49,800 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0001520138-25-000016 · ownership.xml · derivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,800 Underlying: Common Stock · 49,800 shares Expires 2029-11-20 F1 · derivative.exercise_date: The options vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting. Read SEC document |
| August 19, 2024 Filed Aug 26, 2024 23:11 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,000 | $9.47 | $9,465.00 |
DisclosureSEC source: 0001104659-24-092969 · tm2422715-1_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,061 Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 21:28 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,000 | $9.00 | $9,000.00 |
DisclosureSEC source: 0001104659-24-091339 · tm2422188-1_4seq1.xml · nonDerivative · entry 2 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,561 Read SEC document |
| August 14, 2024 Filed Aug 20, 2024 21:28 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,000 | $8.40 | $8,395.40 |
DisclosureSEC source: 0001104659-24-091339 · tm2422188-1_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,561 Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 23,830 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001104659-24-063964 · tm2415098-3_4seq1.xml · derivative · entry 2 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,830 Underlying: Common Stock · 23,830 shares Expires 2031-05-17 F2 · derivative.exercise_date: 1/12th of the options vest on the 17th of the month for twelve months beginning June 17, 2024. Read SEC document |
| May 17, 2024 Filed May 21, 2024 23:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 12,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-063964 · tm2415098-3_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,561 F1 · security: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| April 13, 2024 Filed Apr 17, 2024 00:56 UTC | Celularity Inc CELU · Entity 7145 | Tax withholdingClass A Common Stock | 1,154 | $4.11 | $4,742.94 |
DisclosureSEC source: 0001493152-24-014947 · ownership.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,855,889 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax obligations associated with the vesting and settlement of restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan") and does not represent a sale. F2 · balance_after: Includes 8,688 shares underlying RSUs subject to vesting. Each RSU represents the right to receive one share of the Issuer's Class A common stock subject to vesting. F3 · balance_after: On February 29, 2024, the Issuer effected a 1-for-10 reverse stock split (the "Reverse Stock Split") on its Common Stock. The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:46 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option Grant (Right to Buy) · Derivative | 2,937,788 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001493152-24-007491 · ownership.xml · derivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,937,788 Underlying: Class A Common Stock · 2,937,788 shares Expires 2034-02-15 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2021 Equity Incentive Plan. The shares underlying such option will vest in equal quarterly installments during 2024 such that 25% of the option will vest on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 14, 2023 Filed Dec 19, 2023 00:19 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 800 | $16.89 | $13,512.00 |
DisclosureSEC source: 0001104659-23-127005 · tm2333196-1_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,716 Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 23:02 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,000 | $15.50 | $15,500.00 |
DisclosureSEC source: 0001104659-23-125791 · tm2332860-1_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,516 Read SEC document |
| November 09, 2023 Filed Dec 6, 2023 21:15 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantCommon Stock | 42,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-23-000532 · ownership.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,254 F1 · date: The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on September 22, 2023, subject to board approval, which was obtained on November 9, 2023. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments beginning on February 9, 2024, with the remaining installments vesting on May 9, 2024, August 9, 2024 and the earlier of November 9, 2024 or the date of the issuer's 2024 annual shareholders' meeting. Read SEC document |
| October 05, 2023 Filed Oct 11, 2023 01:48 UTC | Celularity Inc CELU · Entity 7145 | PurchaseClass A Common Stock | 3,050,427 | $0.16 | $483,797.72 |
DisclosureSEC source: 0000950170-23-052758 · ownership.xml · nonDerivative · entry 3 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,570,434 F1 · price: On September 29, 2023, the Reporting Person and Sorrento Therapeutics, Inc. ("Sorrento"), which is in voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Reporting Person agreed (i) to acquire on the date of the signing of the SPA, 9,064,539 shares of the Issuer's Class A common stock for an aggregate amount in cash equal to $1.5 million, payable on such initial closing date, and (ii) to acquire, no later than October 4, 2023, the remaining 11,357,585 shares of the Issuer's Class A common stock owned by Sorrento for an aggregate amount in cash equal to 75% of the 5-Day VWAP of the Issuer's Class A common stock calculated as provided in the SPA. F2 · price: (Continued from Footnote 1): The Reporting Person received 9,064,539 shares of the Issuer's Class A common stock on October 4, 2023. The Reporting Person received 6,307,158 shares of the Issuer's Class A common stock on October 6, 2023. The Reporting Person received the remaining 3,050,427 shares of the Issuer's Class A common stock on October 10, 2023. F3 · balance_after: Includes 98,426 shares underlying RSUs subject to vesting. Each RSU represents the right to receive one share of the Issuer's Class A common stock subject to vesting. Read SEC document |
| October 05, 2023 Filed Oct 11, 2023 01:48 UTC | Celularity Inc CELU · Entity 7145 | PurchaseClass A Common Stock | 6,307,158 | $0.16 | $1,000,315.26 |
DisclosureSEC source: 0000950170-23-052758 · ownership.xml · nonDerivative · entry 2 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,520,007 F1 · price: On September 29, 2023, the Reporting Person and Sorrento Therapeutics, Inc. ("Sorrento"), which is in voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Reporting Person agreed (i) to acquire on the date of the signing of the SPA, 9,064,539 shares of the Issuer's Class A common stock for an aggregate amount in cash equal to $1.5 million, payable on such initial closing date, and (ii) to acquire, no later than October 4, 2023, the remaining 11,357,585 shares of the Issuer's Class A common stock owned by Sorrento for an aggregate amount in cash equal to 75% of the 5-Day VWAP of the Issuer's Class A common stock calculated as provided in the SPA. F2 · price: (Continued from Footnote 1): The Reporting Person received 9,064,539 shares of the Issuer's Class A common stock on October 4, 2023. The Reporting Person received 6,307,158 shares of the Issuer's Class A common stock on October 6, 2023. The Reporting Person received the remaining 3,050,427 shares of the Issuer's Class A common stock on October 10, 2023. F3 · balance_after: Includes 98,426 shares underlying RSUs subject to vesting. Each RSU represents the right to receive one share of the Issuer's Class A common stock subject to vesting. Read SEC document |
| September 29, 2023 Filed Oct 11, 2023 01:48 UTC | Celularity Inc CELU · Entity 7145 | PurchaseClass A Common Stock | 9,064,539 | $0.17 | $1,500,181.20 |
DisclosureSEC source: 0000950170-23-052758 · ownership.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,212,849 F1 · price: On September 29, 2023, the Reporting Person and Sorrento Therapeutics, Inc. ("Sorrento"), which is in voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court"), entered into a Stock Purchase Agreement (the "SPA") pursuant to which the Reporting Person agreed (i) to acquire on the date of the signing of the SPA, 9,064,539 shares of the Issuer's Class A common stock for an aggregate amount in cash equal to $1.5 million, payable on such initial closing date, and (ii) to acquire, no later than October 4, 2023, the remaining 11,357,585 shares of the Issuer's Class A common stock owned by Sorrento for an aggregate amount in cash equal to 75% of the 5-Day VWAP of the Issuer's Class A common stock calculated as provided in the SPA. F2 · price: (Continued from Footnote 1): The Reporting Person received 9,064,539 shares of the Issuer's Class A common stock on October 4, 2023. The Reporting Person received 6,307,158 shares of the Issuer's Class A common stock on October 6, 2023. The Reporting Person received the remaining 3,050,427 shares of the Issuer's Class A common stock on October 10, 2023. F3 · balance_after: Includes 98,426 shares underlying RSUs subject to vesting. Each RSU represents the right to receive one share of the Issuer's Class A common stock subject to vesting. Read SEC document |
| September 06, 2023 Filed Sep 12, 2023 22:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,500 | $13.60 | $20,400.00 |
DisclosureSEC source: 0001104659-23-100116 · tm2325917d1_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,516 Read SEC document |
| May 12, 2023 Filed May 16, 2023 23:27 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 15,125 | $0.00 Strike: $20.05 | $0.00 |
DisclosureSEC source: 0001104659-23-061520 · tm2316016-3_4seq1.xml · derivative · entry 2 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,125 Underlying: Common Stock · 15,125 shares Expires 2030-05-12 F2 · derivative.exercise_date: 1/12th of the options vest on the 12th of the month for twelve months beginning June 12, 2023. Read SEC document |
| May 12, 2023 Filed May 16, 2023 23:27 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 8,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-061520 · tm2316016-3_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,016 F1 · security: Reflects grant of restricted stock rights that vest in full on May 12, 2024, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on May 12, 2024, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| April 13, 2023 Filed Apr 18, 2023 01:19 UTC | Celularity Inc CELU · Entity 7145 | Tax withholdingClass A Common Stock | 11,540 | $0.71 | $8,240.71 |
DisclosureSEC source: 0000899243-23-011343 · doc4.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,148,310 F1 · shares: Represents shares withheld by the Issuer to satisfy its tax withholding obligations associated with the vesting and settlement of restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan") and does not represent a sale. F2 · balance_after: Includes 98,426 shares underlying RSUs subject to vesting. Each RSU represents the right to receive one share of the Issuer's Class A common stock subject to vesting. . Read SEC document |
| March 27, 2023 Filed Mar 28, 2023 00:27 UTC | Celularity Inc CELU · Entity 7145 | GrantWarrants (Right to Buy) · Derivative | 2,084,854 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0000950170-23-010087 · ownership.xml · derivative · entry 2 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,084,854 Underlying: Class A Common Stock · 2,084,854 shares Expires 2028-03-27 F1 · price: On March 27, 2023, the Reporting Person purchased directly from the Issuer (i) 2,084,854 shares of the Issuer's Class A common stock at a price of $0.8343 per share, and (ii) a 5-year immediately exercisable warrant to purchase 2,084,854 shares of the Issuer's Class A common stock at an exercise price of $3.00, at a price of $0.125 per whole share underlying the warrant, or an aggregate purchase price of $2.0 million pursuant to a securities purchase agreement dated March 20, 2023. F1 · derivative.exercise_date: On March 27, 2023, the Reporting Person purchased directly from the Issuer (i) 2,084,854 shares of the Issuer's Class A common stock at a price of $0.8343 per share, and (ii) a 5-year immediately exercisable warrant to purchase 2,084,854 shares of the Issuer's Class A common stock at an exercise price of $3.00, at a price of $0.125 per whole share underlying the warrant, or an aggregate purchase price of $2.0 million pursuant to a securities purchase agreement dated March 20, 2023. Read SEC document |
| March 27, 2023 Filed Mar 28, 2023 00:27 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 2,084,854 | $0.83 | $1,739,393.69 |
DisclosureSEC source: 0000950170-23-010087 · ownership.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,159,850 F1 · price: On March 27, 2023, the Reporting Person purchased directly from the Issuer (i) 2,084,854 shares of the Issuer's Class A common stock at a price of $0.8343 per share, and (ii) a 5-year immediately exercisable warrant to purchase 2,084,854 shares of the Issuer's Class A common stock at an exercise price of $3.00, at a price of $0.125 per whole share underlying the warrant, or an aggregate purchase price of $2.0 million pursuant to a securities purchase agreement dated March 20, 2023. F2 · balance_after: This includes 131,234 shares underlying restricted stock units subject to vesting. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 00:55 UTC | Celularity Inc CELU · Entity 7145 | PurchaseClass A Common Stock | 10,000 | $1.72 | $17,175.00 |
DisclosureSEC source: 0000899243-22-037241 · doc4.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,074,996 F1 · price: This price reported in Column 4 is a weighted-average price. The shares were purchased in multiple transactions at prices ranging from $1.715 to $1.7199, inclusive. The reporting person undertakes to provide to Celularity Inc., any security holder of Celularity Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 00:53 UTC | Celularity Inc CELU · Entity 7145 | PurchaseClass A Common Stock | 40,000 | $1.71 | $68,400.00 |
DisclosureSEC source: 0000899243-22-037162 · doc4.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,064,996 F1 · price: This price reported in Column 4 is a weighted-average price. The shares were purchased in multiple transactions at prices ranging from $1.655 to $1.7799, inclusive. The reporting person undertakes to provide to Celularity Inc., any security holder of Celularity Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 00:13 UTC | Celularity Inc CELU · Entity 7145 | PurchaseClass A Common Stock | 40,000 | $1.74 | $69,600.00 |
DisclosureSEC source: 0000899243-22-037102 · doc4.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,024,996 F1 · price: This price reported in Column 4 is a weighted-average price. The shares were purchased in multiple transactions at prices ranging from $1.625 to $1.8498, inclusive. The reporting person undertakes to provide to Celularity Inc., any security holder of Celularity Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 23, 2022 Filed Jan 18, 2023 21:24 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantCOMMON STOCK | 34,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-23-000057 · ownership.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,240 Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 01:14 UTC | Celularity Inc CELU · Entity 7145 | Exercise / conversionStock Option (Right to Buy) · Derivative | 119,073 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0000899243-22-029784 · doc4.xml · derivative · entry 2 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,287 Underlying: Class A Common Stock · 119,073 shares Expires 2031-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 01:14 UTC | Celularity Inc CELU · Entity 7145 | Exercise / conversionClass A Common Stock | 119,073 | $2.87 | $341,739.51 |
DisclosureSEC source: 0000899243-22-029784 · doc4.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,984,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2022 Filed Aug 16, 2022 22:27 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 2,000 | $43.29 | $86,581.40 |
DisclosureSEC source: 0001104659-22-091871 · tm2223624-1_4seq1.xml · nonDerivative · entry 1 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,911 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.26 to $43.325, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 30, 2022 Filed May 4, 2022 00:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionRestricted Stock Rights · Derivative | 2,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055438 · tm2214402-3_4seq1.xml · derivative · entry 3 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,708 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock rights convert to common stock upon vesting on a one-for-one basis and have no expiration date. F2 · derivative.expiration_date: Restricted stock rights convert to common stock upon vesting on a one-for-one basis and have no expiration date. Read SEC document |
| April 30, 2022 Filed May 4, 2022 00:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 2,708 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055438 · tm2214402-3_4seq1.xml · nonDerivative · entry 2 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock rights convert to common stock upon vesting on a one-for-one basis and have no expiration date. Read SEC document |
| April 29, 2022 Filed May 4, 2022 00:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 13,981 | $0.00 Strike: $22.56 | $0.00 |
DisclosureSEC source: 0001104659-22-055438 · tm2214402-3_4seq1.xml · derivative · entry 4 Hariri Robert J · CIK 0001398815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,981 Underlying: Common Stock · 13,981 shares Expires 2029-04-29 F3 · derivative.exercise_date: 1/12th of the options vest on the 30th of the month for twelve months beginning May 30, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.